RxDoctor Payments Data

Steven Jacobson, MD

Internal Medicine · Sarasota, FLNPI 1558369702

Payments from drug & device makers

$655in general payments, 2019–2025

Across 36 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$132
  • Tosoh Bioscience, Inc.$112
  • Pfizer$82
  • AbbVie$80
  • Abbott$77
  • Johnson & Johnson$64
  • plus $109 from 6 others

What the payments were for

  • Food & beverage$54383%
  • Gifts$11217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$655 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$16,061
Medicare patients
105
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$104,704
JardianceEmpagliflozin77$67,536
TrulicityDulaglutide30$56,147
XareltoRivaroxaban31$39,360
OzempicSemaglutide23$37,094
Breo ElliptaFluticasone/Vilanterol19$13,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$10,811
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$4,436
Rosuvastatin Calcium144$2,350
Gabapentin114$2,216
Atorvastatin Calcium281$2,090
Duloxetine Hcl118$2,021
Varenicline Tartrate13$1,983
Pregabalin31$1,728
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$104,70486 claims
Lilly USA, LLCTrulicity$27$56,14730 claims
Johnson & JohnsonXarelto$64$39,36031 claims
GSKBreo Ellipta, Trelegy Ellipta$12$24,01337 claims
AbbVieSynthroid$80$1,10914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →